Interviews

The FIDELIO-DKD program is perhaps just the beginning of seeing how finerenone can be used, said Rajiv Agarwal, MD, MS, FASN, a professor of medicine at Indiana University School of Medicine and a staff physician at the Veterans Affairs Medical Center in Indianapolis, Indiana.

Patricia K. Coyle, MD, of Stony Brook University Neurosciences Institute, explains how studies are trying to answer a debate about 2 approaches to treat multiple sclerosis (MS).

Treatment targets include several interleukins, immunoglobulin E, and alarmins, pointed out Nicola Hanania, MD, MS, pulmonary critical care physician and director, Airway Clinical Research Center, Baylor College of Medicine, Houston.

If you only experience migraine with your period for a few days, it would be difficult to recommend taking a drug all the time, said Stephen Silberstein, MD, professor of neurology at Thomas Jefferson University and director of the Headache Center at Jefferson Health.

What is feasible for one person may be unaffordable for another, said Milena Murray, PharmD, MSc, BCIDP, AAHIVP, associate professor, Midwestern University Chicago College of Pharmacy, who practices at the Northwestern Medicine Infectious Disease Center.

Lametra Scott, PharmD, CCHP, CEO of Breaking The Sickle Cell Cycle Foundation Inc discusses the current standard of care in sickle cell disease (SCD) and the unmet needs facing patients.

Categorizing by eosinophilic/noneosinophilic subtype enables better targeted treatment, noted Anne Reihman, MD, third-year pulmonary and critical care fellow, University of Colorado, Division of Pulmonary Sciences and Critical Care Medicine.

Combination bronchodilators are available and have been shown to improve both symptoms and lung function, explained Nicola Hanania, MD, MS, of Baylor College of Medicine.

Ruth Ann Marrie, MD, PhD, director of the Multiple Sclerosis Clinic at the University of Manitoba, speaks about the overall prevalence of comorbidities in patients with multiple sclerosis (MS).

In collaboration with the American Heart Association, Jazz Pharmaceuticals will provide a wide variety of sleep health educational content, including scientific research, reading materials for both patients and practitioners, and podcasts from experts in the field speaking to the importance of sleep on cardiovascular health.

Partnering with pharmacists ensures prescription availability for patients with HIV during the coronavirus disease 2019 (COVID-19), noted Milena Murray, PharmD, MSc, BCIDP, AAHIVP, of Midwestern University College of Pharmacy.

The CGRP story is really based on reverse translation and other observations in humans will be pursued along that same model, said Frank Porreca, PhD, professor of pharmacology and anesthesiology at the University of Arizona and a member of the Department of Collaborative Research at Mayo Clinic in Arizona.

Immune-associated neurotoxicity in patients following chimeric antigen receptor (CAR) T-cell therapy may be due to monocyte-like cells in infusion products, explained Michael R. Green, PhD, University of Texas MD Anderson Cancer Center.

There is a lot of uncertainty among providers participating in federal alternative payment models (APMs) given the general election and the upcoming Supreme Court case on the Affordable Care Act (ACA).

Despite FDA accelerated approval in April, we still need to learn more about resistance to this antibody drug conjugate, said Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.

Lametra Scott, PharmD, CCHP, CEO of Breaking The Sickle Cell Cycle Foundation Inc, discussed the pathophysiology of sickle cell disease (SCD) the dangers of leaving it untreated.

The federal illegality and Schedule I listing of cannabis significantly impair our ability to conduct any kind of prospective clinical research, said Joshua L Rein, DO, FASN, a nephrologist at Mt. Sinai Hospital in New York City.

Despite the price, adherence to biologics for asthma is usually good because of the effectiveness, said J. Allen Meadows, MD, president of the American College of Allergy, Asthma & Immunology.

Jill Jarecki, PhD, chief scientific officer at Cure SMA explained the current data and potential for gender to impact the severity spinal muscular atrophy (SMA).

The patients must always come first, emphasized Milena Murray, PharmD, MSc, BCIDP, AAHIVP, associate professor at Midwestern University College of Pharmacy, who practices at the Northwestern Medicine Infectious Disease Center in Chicago.

Spend time with your patients, discussing both the risks and benefits of a potential coronavirus disease 2019 vaccine, emphasized Maura Abbott, PhD, AOCNP, CPNP, RN, assistant professor of nursing at the Columbia University School of Nursing.

Quality of life for patients with multiple sclerosis (MS) could be better when they are off medication because they will not have adverse effects related to those medications, said John Corboy, MD, professor of neurology, University of Colorado Denver, School of Medicine.

Major issues still surround COPD treatment, noted Nicola Hanania, MD, MS, pulmonary critical care physician and director, Airway Clinical Research Center, Baylor College of Medicine, Houston, Texas.

Michael S. Fitts, assistant dean for user access and diversity for The University of Alabama at Birmingham, discusses reporting on the progressive symptoms of Parkinson disease, and the impact of nonmotor symptoms of anxiety and depression.

There can be a myriad of reasons for the patterns observed in our study on alteration of migraine frequency and triggers during the pandemic, said Faraidoon Haghdoost, MD, a general practitioner and PhD student at The George Institute for Global Health in Sydney, Australia.

Much of the population experiences disordered breathing at night, explained Krishna M. Sundar, MD, clinical professor, Pulmonary Division, Department of Medicine, and medical director, Sleep-Wake Center, University of Utah.

Initial preliminary efficacy and safety data are expected sometime next year, stated Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.

Early treatment of infants with spinal muscular atrophy (SMA) can drastically improve motor function for patients, explained Jill Jarecki, PhD, chief scientific officer at Cure SMA.